Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) EBITDA
Solventum Corporation's EBITDA for fiscal 2025 was $2.7B, up 67.8% from $1.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.6B. Solventum Corporation ranks 5th of 51 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $2.7B | 67.82% |
| FY2024 | $1.6B | (29.38%) |
| FY2023 | $2.3B | (0.79%) |
| FY2022 | $2.3B | — |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $314.0M | 46.05% |
| Mar 2026 | $215.0M | (11.16%) |
| Dec 2025 | $242.0M | (86.64%) |
| Sep 2025 | $1.8B | 438.99% |
| 10 more quarters | Free account |
EBITDA against peers
| Company | EBITDA |
|---|---|
| ALC Alcon compare | $2.7B |
| SOLV Solventum Corporation | $2.6B |
| BAX Baxter International Inc. compare | $1.5B |
| COO The Cooper Companies, Inc. compare | $928.2M |
| WST West Pharmaceutical Services, Inc. compare | $861.8M |
| ALGN Align Technology, Inc. compare | $802.0M |
| ATR AptarGroup, Inc. compare | $784.6M |
| RGEN Repligen Corporation compare | $161.0M |
| AVTR Avantor, Inc. compare | $124.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SOLV
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement